Drug Trial Radar · NCT06517823
Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain
Last checked: Nov 20, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
190
Actual
Start
Apr 26, 2024
Primary completion
Oct 4, 2024
Study completion Oct 11, 2024
Sponsor
- Lead sponsor
- Laboratorios Silanes S.A. de C.V.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib/Cyanocobalamin Versus Etoricoxib in Patients With Acute Low Back Pain
Conditions
- Acute Low-back Pain
Interventions
Etoricoxib + Cyanocobalamin fixed doseDrug
One tablet of 90 mg / 0.50 mg a day
Etoricoxib fixed doseDrug
One pill of 90 mg a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the proportion of patients reporting pain improvement (reduction in pain intensity with a VAS ≤20 mm) at 1, 3, 5, and 7 days of follow-up, according to their baseline measurement in each treatment groupTime frame: 7 dyas
- Number of participants with treatment-related adverse events through the patient's diary record.Time frame: 7 dyas
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laboratorio Silanes, S.A. de C.V.
Mexico City, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.